1. Huggins C. HC Studies on prostatic cancer: 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293.
2. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968;243:2012–21.
3. Rennie PS, Bruchovsky N, Leco KJ, et al. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993;7:23–36.
4. van Poppel H, Nilsson S. Testosterone surge: Rationale for gonadotropin-releasing hormone blockers? Urology 2008;71:1001–6.
5. Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58:5–9.
6. Labrie F, Dupont A, Belanger A, et al. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem 1983;19:999–1007.
7. Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585–9.
8. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531–8.
9. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990;144:1479–80.
10. Ohuchi H, Noguchi K, Kinoshita Y, et al. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients. Hinyokika Kiyo 2000;46:531–6.
11. Appu S, Lawrentschuk N, Grills RJ, et al. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer. J Urol 2005;174:140–2.
12. Kuhn JM, Billebaud T, Navratil H, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989;321:413–8.
13. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systemic review and meta-analysis. Ann Intern Med 2000;132:566–77.
14. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration in patients with prostate cancer receiving continous androgen deprivation therapy. J Urol 2007;178:1290–5.
15. Schroder FH, Tombal B, Miller K, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int 2010;106:182–7.
16. Robinson D, Sandblom G, Johansson R, et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol 2008;179:117–22; discussion 122–3.
17. Tombal B, Miller K, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010;57:836–42.
18. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms.
19. Perachino M, Cavalli V, Bravi F. Testosteron levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2009;105:648–51.
Dr. Christoph Rüssel, Facharzt für Urologie und Medikamentöse Tumortherapie, Neutor 28–32, 46325 Borken, E-Mail: firstname.lastname@example.org